Abstract:Platelets aggregation and thrombosis formation are major reasons of cardiovascular and cerebral vascular diseases.To develop new generative,potent and safe agents for inhibiting platelet aggregation and preventing above diseases are urgently required.Some traditional Chinese medicines of″Houxue Huayu″have been shown to inhibit platelet aggregation potently.In the present study the mechanisms and the molecular targets of puerarin,salvianolic acid B and the analogue of 3-n-butylphthalide,dl-PHPB were investigated and compared with ticlopidine.Four platelet aggregation inducers,ADP,arachidonic acid,collagen and thrombin were used in the study.It was found that puerarin and dl-PHPB specifically inhibited ADP induced platelet aggregation like ticlopidine did.However,salvianolic acid B inhibited both ADP and collagen induced platelet aggregations with similar potency.Due to existing two ADP receptor subtypes on platelets,P2Y1 and P2Y12,we studied the action of above compounds on the receptors and the signaling pathways.It was found that dl-PHPB decreased IP1 accumulation produced by ADP,but had no effect on IP1 level induced by m-3M3 FBS,an activator of PLC.M-3M3 FBS might attenuate the inhibitory effect of dl-PHPB on ADP-induced platelet aggregation.In addition,dl-PHPB did not affect cyclic AMP formation in platelets by ADP,which is different from P2Y12 antagonist ticlopidine.Puerarin showed the similar effects of dl-PHPB.Therefore,the actions of dl-PHPB and puerarin might be through P2Y1receptor-PLC-βpathway.Salvianolic acid B did not reduce the IP1 accumulation stimulated by ADP.It might act on the receptor subtype P2Y12.Our results suggest that components of Chinese herb medicine might be a resource for development of novel anti-platelet drugs.

Synthesis Of Ligustrazine-Aromatic Acid Derivatives And Their Inhibitory Effect On Platelet Aggregation

Synthesis of Novel Ligustrazine Derivatives As Potential Platelet Aggregation Inhibitors

Synthesis and Evaluation of Novel Nitric Oxide-Donating Ligustrazine Derivatives as Potent Antiplatelet Aggregation Agents

Ligustrazine derivatives. Part 5: design, synthesis and biological evaluation of novel ligustrazinyloxy-cinnamic acid derivatives as potent cardiovascular agents.

Design, Synthesis and Evaluation of Novel 2-Amino-3-(naphth-2-yl)propanoic Acid Derivatives As Potent Inhibitors of Platelet Aggregation

Design, Synthesis, and Biological Activities of Novel Ligustrazine Derivatives.

Synthesis of 2H-Benzo[b][1,4]oxazin-3(4h)-one Derivatives As Platelet Aggregation Inhibitors.

ChemInform Abstract: Ligustrazine Derivatives. Part 5. Design, Synthesis and Biological Evaluation of Novel Ligustrazinyloxy‐Cinnamic Acid Derivatives as Potent Cardiovascular Agents.

Design, Synthesis and Evaluation of 1,4-Benzodioxine Derivatives As Novel Platelet Aggregation Inhibitors.

Design, synthesis and biological evaluation of novel ligustrazinylated derivatives as potent cardiovascular agents

1,4-Benzoxazine-3(4H)-ones as potent inhibitors of platelet aggregation: design, synthesis and structure-activity relations.

Synthesis of 3,15-Disuccinate-12-coumarin Substituted Andrographolide Derivatives and Their Antiplatelet Aggregation Activities in Vitro

Ligustrazine Derivatives. Part 8: Design, Synthesis, and Preliminary Biological Evaluation of Novel Ligustrazinyl Amides As Cardiovascular Agents

Synthesis and Biological Evaluation of Ticagrelor Derivatives As Novel Antiplatelet Agents.

Synthesis and evaluation of L-quebrachitol derivatives against platelet aggregation

Design, Synthesis and Biological Evaluation of Novel Trimethylpyrazine-2-carbonyloxy-cinnamic Acids As Potent Cardiovascular Agents

Ligustrazine derivatives. Part 6: design, synthesis and evaluation of novel ligustrazinyl acylguanidine derivatives as potential cardiovascular agents.

Lancolides, antiplatelet aggregation nortriterpenoids with tricyclo[6.3.0.02,11]undecane-bridged system from Schisandra lancifolia

Synthesis and NHE1 Inhibitory Activity of Ligustrazine Derivatives

Ligustrazine derivatives. Part 3: Design, synthesis and evaluation of novel acylpiperazinyl derivatives as potential cerebrocardiac vascular agents.

Components of Traditional Chinese Medicine Inhibit Platelet Aggregation by Blocking ADP Receptor Subtypes P2Y1 and P2Y12